Panitumumab and Cetuximab Affect Differently Mirna Expression in Colorectal Cancer Cells

References

• Jass JR , WhitehallVLJ, YoungJ, LeggettBA. Emerging concepts in colorectal neoplasia. Gastroenterology123(3), 862–876 (2002).
   PubMed Web of Science ®Google Scholar
• Gazzeri S . L'EGFR nucléaire: un nouveau mode de signalisation dans les cancers. Biologie Aujourd'hui212(1–2), 27–33 (2018).
   PubMedGoogle Scholar
• Bianco R , GelardiT, DamianoV, CiardielloF, TortoraG. Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol.39(7–8), 1416–1431 (2007).
   PubMed Web of Science ®Google Scholar
• Wheeler DL , DunnEF, HarariPM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol.7(9), 493–507 (2010).
   PubMed Web of Science ®Google Scholar
• Bibeau F , Lopez-CrapezE, DiFiore Fet al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol.27(7), 1122–1129 (2009).
   PubMed Web of Science ®Google Scholar
• Trivedi S , SrivastavaRM, Concha-BenaventeFet al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin. Cancer Res.22(21), 5229–5237 (2016).
   PubMedGoogle Scholar
• Price TJ , PeetersM, KimTWet al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority Phase III study. Lancet Oncol.15(6), 569–579 (2014).
   PubMed Web of Science ®Google Scholar
• Linardou H , DahabrehIJ, KanaloupitiDet al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol.9(10), 962–972 (2008).
   PubMed Web of Science ®Google Scholar
• Lièvre A , BachetJ-B, BoigeVet al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Vaughn CP , ZobellSD, FurtadoLV, BakerCL, SamowitzWS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer50(5), 307–312 (2011).
   PubMed Web of Science ®Google Scholar
• Friedman RC , FarhKK-H, BurgeCB, BartelDP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res.19(1), 92–105 (2009).
   PubMed Web of Science ®Google Scholar
• Peng Y , CroceCM. The role of microRNAs in human cancer. Signal Transduct. Target. Ther.1, 15004 (2016).
   PubMed Web of Science ®Google Scholar
• Han L , WitmerPD, CaseyE, ValleD, SukumarS. DNA methylation regulates microRNA expression. Cancer Biol. Ther.6(8), 1284–1288 (2007).
   PubMed Web of Science ®Google Scholar
• Schetter AJ , HarrisCC. Alterations of microRNAs contribute to colon carcinogenesis. Semin. Oncol.38(6), 734–742 (2011).
   PubMed Web of Science ®Google Scholar
• Mlcochova J , FaltejskovaP, NemecekR, SvobodaM, SlabyO. MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J. Cancer Res. Clin. Oncol.139(10), 1615–1624 (2013).
   PubMed Web of Science ®Google Scholar
• Manceau G , ImbeaudS, ThiébautRet al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res.20(12), 3338–3347 (2014).
   PubMed Web of Science ®Google Scholar
• Mlcochova J , Faltejskova-VychytilovaP, FerracinMet al. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget6(36), 38695–38704 (2015).
   PubMedGoogle Scholar
• Mosakhani N , LahtiL, BorzeIet al. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet.205(11), 545–551 (2012).
   PubMed Web of Science ®Google Scholar
• Pichler M , WinterE, RessALet al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J. Clin. Pathol.67(3), 198–203 (2014).
   PubMed Web of Science ®Google Scholar
• Suto T , YokoboriT, YajimaRet al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis36(3), 338–345 (2015).
   PubMedGoogle Scholar
• Lu Y , ZhaoX, LiuQet al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. Nat. Med.23(11), 1331–1341 (2017).
   PubMed Web of Science ®Google Scholar
• Sun L , FangY, WangXet al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics9(26), 8409–8425 (2019).
   PubMed Web of Science ®Google Scholar
• Dahan L , SadokA, FormentoJ-L, SeitzJF, KovacicH. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br. J. Pharmacol.158(2), 610–620 (2009).
   PubMed Web of Science ®Google Scholar
• Riffo-Campos ÁL , RiquelmeI, Brebi-MievilleP. Tools for sequence-based miRNA target prediction: what to choose?Int.J. Mol. Sci.17(12), 1987 (2016).
   PubMed Web of Science ®Google Scholar
• Witkos TM , KoscianskaE, KrzyzosiakWJ. Practical aspects of microRNA target prediction. Curr. Mol. Med.11(2), 93–109 (2011).
   PubMed Web of Science ®Google Scholar
• Kanehisa M , SatoY, KawashimaM, FurumichiM, TanabeM. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res.44(D1), D457–462 (2016).
   PubMed Web of Science ®Google Scholar
• To KK , TongCW, WuM, ChoWC. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. World J. Gastroenterol.24(27), 2949–2973 (2018).
   PubMed Web of Science ®Google Scholar
• Voigt M , BraigF, GöthelMet al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia14(11), 1023–1031 (2012).
   PubMed Web of Science ®Google Scholar
• Kim GP , GrotheyA. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics2(2), 223–228 (2008).
   PubMedGoogle Scholar
• García-Foncillas J , SunakawaY, AderkaDet al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front. Oncol.9, 849 (2019).
   PubMed Web of Science ®Google Scholar
• Ragusa M , MajoranaA, StatelloLet al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol. Cancer Ther.9(12), 3396–3409 (2010).
   PubMed Web of Science ®Google Scholar
• Fan X , KurganL. Comprehensive overview and assessment of computational prediction of microRNA targets in animals. Brief. Bioinformatics16(5), 780–794 (2015).
   PubMedGoogle Scholar
• Liang J , ZhouW, SakreNet al. Epigenetically regulated miR-1247 functions as a novel tumour suppressor via MYCBP2 in methylator colon cancers. Br. J. Cancer119(10), 1267–1277 (2018).
   PubMedGoogle Scholar
• Sur D , CainapC, BurzCet al. The role of miRNA-31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs? J. BUON 24(5), 1739–1746 (2019).
   PubMedGoogle Scholar
• Igarashi H , KuriharaH, MitsuhashiKet al. Association of microRNA-31-5p with clinical efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer. Ann. Surg. Oncol.22(8), 2640–2648 (2015).
   PubMed Web of Science ®Google Scholar
• Pugh S , ThiebautR, BridgewaterJet al. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the new EPOC trial. Oncotarget8(55), 93856–93866 (2017).
   PubMedGoogle Scholar
• Laurent-Puig P , GrisoniML, HeinemannVet al. Validation of miR-31-3p expression to predict cetuximab efficacy when used as first-line treatment in RAS wild-type metastatic colorectal cancer. Clin. Cancer Res.25(1), 134–141 (2019).
   PubMed Web of Science ®Google Scholar
• Kent OA , MendellJT, RottapelR. Transcriptional regulation of miR-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1. Mol. Cancer Res.14(3), 267–277 (2016).
   PubMedGoogle Scholar
• Nosho K , IgarashiH, NojimaMet al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis35(4), 776–783 (2014).
   PubMed Web of Science ®Google Scholar
• Tovar-Camargo OA , TodenS, GoelA. Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers. Expert Rev. Mol. Diagn.16(5), 553–567 (2016).
   PubMed Web of Science ®Google Scholar
• Gallo A , TandonM, AlevizosI, IlleiGG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE7(3), e30679 (2012).
   PubMed Web of Science ®Google Scholar
• Turchinovich A , WeizL, LangheinzA, BurwinkelB. Characterization of extracellular circulating microRNA. Nucleic Acids Res.39(16), 7223–7233 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang J , LiS, LiLet al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics13(1), 17–24 (2015).
   PubMed Web of Science ®Google Scholar
• Liu X , PanB, SunLet al. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Cancer Epidemiol. Biomarkers Prev.27(7), 746–754 (2018).
   PubMed Web of Science ®Google Scholar
• Matsumura T , SugimachiK, IinumaHet al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br. J. Cancer113(2), 275–281 (2015).
   PubMed Web of Science ®Google Scholar
• Ogata-Kawata H , IzumiyaM, KuriokaDet al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS ONE9(4), e92921 (2014).
   PubMed Web of Science ®Google Scholar
• Wang J , YanF, ZhaoQet al. Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer. Sci. Rep.7(1), 4150 (2017).
   PubMedGoogle Scholar
• Zhang H , ZhuM, ShanXet al. A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Gene687, 246–254 (2019).
   PubMed Web of Science ®Google Scholar